Lenalidomide Grindeks

Lenalidomide, the active ingredient in Lenalidomide Grindeks, is an Immunomodulatory imide drug (IMiD) presented as an oral formulation for oral use. It is indicated for the treatment of multiple myeloma and myelodysplastic syndromes with del(5q) in appropriate patients.

GNH USA supplies Lenalidomide Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide is used in hematologic malignancies and related disorders, acting on abnormal plasma cells and dysplastic marrow clones. - Multiple Myeloma: improves disease control and prolongs progression‑free survival. - Myelodysplastic Syndromes with del(5q): reduces transfusion requirements and may improve blood counts. - Relapsed or refractory disease: offers an option when prior therapies have failed.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness reported by many patients. - Diarrhea: mild to moderate gastrointestinal upset. - Rash: skin irritation or erythema. - Constipation: reduced bowel movements. - Nausea: occasional feeling of sickness. - Musculoskeletal pain: aches in joints or muscles.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly low neutrophil counts increasing infection risk. - Secondary malignancies: rare development of new cancers. - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Cardiac arrhythmias: irregular heart rhythms in susceptible individuals.

Before initiating Lenalidomide therapy, clinicians should assess patient history and monitor relevant parameters. - Pregnancy risk: avoid use in pregnant women; teratogenic potential requires strict contraception. - Thrombosis risk: evaluate for clotting disorders and consider prophylactic anticoagulation. - Renal function: adjust monitoring for patients with impaired kidney function. - Hepatic function: monitor liver enzymes regularly. - Infection vigilance: watch for signs of infection due to neutropenia. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Lenalidomide may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may reduce plasma concentrations of Lenalidomide. - Anticoagulants (e.g., warfarin): increased risk of bleeding.

Moderate Interactions (Monitor Closely): - Immunosuppressants: heightened infection risk. - P-glycoprotein inhibitors: potential increase in drug exposure. - NSAIDs: may exacerbate renal toxicity. - Vaccines (live): reduced vaccine efficacy. - Other myelosuppressive agents: additive bone‑marrow suppression.